Mankind Pharma’s modern trade and e-commerce mix rises to 15% in Q1 FY27

Mankind Pharma’s consumer healthcare business grew 4% in Q1 FY27, while modern trade and e-commerce expanded 38% and increased their revenue contribution to 15%, from 11% a year earlier. Overall revenue rose 13% and EBITDA margin expanded to 26.2%.

— Source publishedThu, 30 Jul, 2026, 16:34 IST·First seen Thu, 30 Jul, 2026, 16:43 IST·Source CNBC-TV18 · Companies

What happened

Mankind Pharma posted strong Q1 FY27 earnings, led by domestic chronic therapies and margin expansion. Consumer healthcare grew 4%, while modern trade and

Key facts

  • Q1 FY27 net profit: ₹568 crore, up 30% YoY
  • Revenue from operations: ₹4,031 crore, up 13% YoY
  • EBITDA: ₹1,057 crore, up 25% YoY
  • EBITDA margin: 26.2%, versus 23.7% a year earlier
  • Domestic business excluding consumer healthcare: up 11%
  • Chronic portfolio: up 15.8%; cardiac: up 19.4%; anti-diabetes: up 12.7%
  • Consumer healthcare revenue: up 4%
  • Modern trade and e-commerce contribution: 15%, versus 11% a year earlier; channel growth: 38%
  • International business revenue: up 29%

Why this matters

Mankind’s expanding omnichannel reach increases the strategic value of digital-native consumer-health brands and distribution partnerships that can accelerate premium, scalable channel mix.

What to watch

  • Modern trade and e-commerce mix crossing 18% to 20% of consumer healthcare sales.
  • Whether consumer healthcare growth rises above the reported 4% as digital-channel gains broaden beyond channel shift.
  • Gross-margin and EBITDA-margin movement within consumer healthcare versus the 26.2% company EBITDA margin.
  • Growth in quick-commerce versus conventional marketplaces, including discount and fulfillment-cost intensity.
  • Evidence of higher repeat rates, premium SKU mix and new-product contribution in digital channels.
  • Competitor promotional responses from OTC, wellness and personal-care brands in marketplaces and modern retail.
  • Prioritize e-commerce-exclusive bundles, trial packs and premium OTC/wellness variants rather than replicating general-trade assortments.
  • Use marketplace and quick-commerce data to identify high-repeat SKUs, then direct inventory and media spending toward profitable city-SKU combinations.
  • Expand omnichannel availability through pharmacy chains, modern trade and rapid-delivery partners while protecting price parity across channels.
  • Track channel-specific contribution margins, returns, ad spending and discount intensity to prevent mix-led EBITDA dilution.
  • Use digital channel traction to support new consumer-health launches and cross-sell into existing high-awareness brands.